132 related articles for article (PubMed ID: 37244767)
1. Are magnetic resonance imaging and targeted biopsies needed in men with serum prostate-specific antigen over 10 ng/ml and an abnormal digital rectal examination?
Morote J; Picola N; Paesano N; Celma A; Muñoz-Rodriguez J; Asiain I; Ruiz-Plazas X; Muñoz-Rivero MV; de Manuel GG; Servian P; Abascal JM
Urol Oncol; 2023 Jul; 41(7):299-301. PubMed ID: 37244767
[TBL] [Abstract][Full Text] [Related]
2. Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia.
Morote J; Borque-Fernando Á; Esteban LE; Picola N; Muñoz-Rodriguez J; Paesano N; Ruiz-Plazas X; Muñoz-Rivero MV; Celma A; García-de Manuel G; Miró B; Abascal JM; Servian P
Urol Oncol; 2024 Apr; 42(4):115.e1-115.e7. PubMed ID: 38342654
[TBL] [Abstract][Full Text] [Related]
3. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis.
Avolio PP; Lughezzani G; Paciotti M; Maffei D; Uleri A; Frego N; Hurle R; Lazzeri M; Saita A; Guazzoni G; Casale P; Buffi NM
Urol Oncol; 2021 Dec; 39(12):832.e1-832.e7. PubMed ID: 34183255
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
Filson CP; Natarajan S; Margolis DJ; Huang J; Lieu P; Dorey FJ; Reiter RE; Marks LS
Cancer; 2016 Mar; 122(6):884-92. PubMed ID: 26749141
[TBL] [Abstract][Full Text] [Related]
5. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
Buisset J; Norris JM; Puech P; Leroy X; Ramdane N; Drumez E; Villers A; Olivier J
J Urol; 2021 Mar; 205(3):725-731. PubMed ID: 33080153
[TBL] [Abstract][Full Text] [Related]
6. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of an organised population-based testing programme for prostate cancer.
Alterbeck M; Thimansson E; Bengtsson J; Baubeta E; Zackrisson S; Bolejko A; Sandeman K; Carlsson S; Jiborn T; Bjartell A
BJU Int; 2024 Jan; 133(1):87-95. PubMed ID: 37523331
[TBL] [Abstract][Full Text] [Related]
8. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
9. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.
Lokeshwar SD; Nguyen J; Rahman SN; Khajir G; Ho R; Ghabili K; Leapman MS; Weinreb JC; Sprenkle PC
Urol Oncol; 2022 Sep; 40(9):407.e21-407.e27. PubMed ID: 35811206
[TBL] [Abstract][Full Text] [Related]
11. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
13. Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?
Leow JJ; Koh SH; Chow MW; Loke W; Salada R; Hong SK; Yeow Y; Lee CH; Tan CH; Tan TW
Asian J Androl; 2023; 25(1):43-49. PubMed ID: 35488666
[TBL] [Abstract][Full Text] [Related]
14. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J
Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
16. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
17. Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation.
Chiu PK; Leow JJ; Chiang CH; Mok A; Zhang K; Hsieh PF; Zhu Y; Lam W; Tsang WC; Fan YH; Lin TP; Chan TY; Leung CH; Teoh JY; Chu PS; Zhu G; Ye DW; Wu HC; Tan TW; Tsu JH; Ng CF; Chiong E; Huang CY
J Urol; 2023 Jul; 210(1):88-98. PubMed ID: 37036248
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.
Numao N; Yoshida S; Komai Y; Ishii C; Kagawa M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
J Urol; 2013 Aug; 190(2):502-8. PubMed ID: 23473904
[TBL] [Abstract][Full Text] [Related]
20. Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
Williams C; Ahdoot M; Daneshvar MA; Hague C; Wilbur AR; Gomella PT; Shih J; Khondakar N; Yerram N; Mehralivand S; Gurram S; Siddiqui M; Pinsky P; Parnes H; Merino M; Wood B; Turkbey B; Pinto PA
J Urol; 2022 Jan; 207(1):95-107. PubMed ID: 34433302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
